Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-...
On Friday, Summit Therapeutics Inc SMMT shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc SMMT announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of …